Hydrothorax exosome metabolite combination, kit and method for diagnosing tuberculous pleurisy

Abstract

The invention relates to a hydrothorax exosome metabolite combination, a kit and a method for diagnosing tuberculous pleurisy. The hydrothorax exosome metabolite combination for diagnosing the tuberculous pleurisy is prepared from dimethylglycine, choline, acyl carnitine with the ratio of 10: 2, phosphatidylcholine with the ratio of 35: 6, phosphatidylcholine o with the ratio of -36: 0, phosphatidylethanolamine with the ratio of 33: 2, sphingomyelin with the ratio of 28: 1 and oleic acid. The kit for diagnosing the tuberculous pleurisy comprises an internal standard substance required for detecting the concentration of the metabolites in the hydrothorax exosome sample extraction solution. A combined marker provided by the invention has the characteristics of high sensitivity and high specificity for the diagnosis of tuberculous pleurisy, and meanwhile, can be complementary with the traditional marker adenosine deaminase, and can be used for the auxiliary diagnosis of the tuberculous pleurisy by being combined with the traditional marker adenosine deaminase.

Description

technical field [0001] The invention relates to a diagnosis method for tuberculous pleurisy, in particular to a combination of pleural effusion exosome metabolites, a kit and a method for diagnosing tuberculous pleurisy. Background technique [0002] Tuberculous pleurisy is a common clinical extrapulmonary tuberculosis with a relatively high incidence, accounting for about 44.1% of the total pleural diseases. In my country, the incidence of malignant pleurisy is as high as 900,000 per year, accounting for about 9% of the world's total. The morbidity and mortality rate of lung cancer is one of the highest tumors in the world, and about 40% of lung cancer patients will have malignant pleural effusion during the disease process. At present, due to the limitations of diagnostic techniques, the proportion of confirmed cases is very low. However, the prognosis and treatment of tuberculous pleurisy and malignant pleurisy are completely different. If not diagnosed and treated in ti...

AI Technical Summary

Problems solved by technology

[0003] At present, the methods for clinical diagnosis and identification of tuberculous pleurisy and malignant pleurisy include clinical manifestations, thoracentesis test results, pleural biopsy, bronchoscopy, surgical biopsy, etc. The most commonly used method is thoracentesis for cytological examination. Tumor cells found in pleural effusion have diagnostic value for malignant pleurisy, but due to the complex cell components in pleural effusion, it is sometimes difficult to distinguish tumor cells from inflammatory mesothelial cells, macrophages, etc. Influenced by other factors, its sensitivity is low (about 40%-60%), and the disadvantages of strong subjectivity are likely to cause missed diagnosis or misdiagnosis; while the diagnosis of tuberculous pleurisy mainly includes pleural effusion biochemical examination, tuberculin skin test ( TST), pleural effusion bacteriological examination (acid-fast stained smear and Mycobacterium tuberculosis culture), pleural histopathological biopsy, etc.

However, the specificity and sensitivity of the above-mentioned inspection methods are low, and some methods are invasive, high-risk, or have a long time period, which cannot meet the needs of clinical work. Therefore, the development of new and highly sensitive diagnostic techniques for pleurisy has very important clinical significance.

Images